Bayesian Statistics Approach Offers Benefits To Sponsors, FDA Staffers Say
This article was originally published in The Gray Sheet
Executive Summary
Use of Bayesian statistics in designing Guidant's Multi-Link Duet stent trial would have halved the number of enrollees required for FDA approval, according to Guidant Senior Biostatistician Frank Hu.
You may also be interested in...
CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required
FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.